Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter

References

• Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23–57
   PubMed Web of Science ®Google Scholar
• Kanis JA, Compston J, Cooper C, et al. The burden of fractures in the European Union in 2010. Osteoporos Int 2012; 23(Suppl 2):S57
   Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 2007; 18:711–19
   PubMed Web of Science ®Google Scholar
• Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: A critical review of the literature. Rev Endocr Metab Disord 2010;11:275–80
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18: 1023–31
   PubMed Web of Science ®Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259–62
   PubMed Web of Science ®Google Scholar
• Vytrisalova M, Blazkova S, Palicka V, et al. Self-reported compliance with osteoporosis medication – qualitative aspects and correlates. Maturitas 2008;60:223–9
   PubMed Web of Science ®Google Scholar
• Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 2011;22:21–6
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223–31
   PubMed Web of Science ®Google Scholar
• Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331–42
   PubMed Web of Science ®Google Scholar
• Schousboe JT. Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep 2013;11: 21–9
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–7
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555–67
   PubMed Web of Science ®Google Scholar
• Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour. J Psychosom Res 2005;58:403–15
   PubMed Web of Science ®Google Scholar
• Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res 2008;64:47–54
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 2010; 21:1899–909
   PubMed Web of Science ®Google Scholar
• Reynolds K, Viswanathan HN, O’Malley CD, et al. Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 2012;46:659–70
   PubMed Web of Science ®Google Scholar
• Matoulkova P, Krulichova IS, Macek K, et al. Chronically ill Czech patients’ beliefs about medicines; the psychometric properties and factor structure of the BMQ-CZ. Therapeutic Innovation & Regulatory Sci 2013, 47:341–8
   Web of Science ®Google Scholar
• Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol 2011;64:255–7; discussion 258–63
   PubMed Web of Science ®Google Scholar
• Breuil V, Cortet B, Cotté FE, et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 2012;23:445–55
   PubMed Web of Science ®Google Scholar
• Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol 2011;64:250–4
   PubMed Web of Science ®Google Scholar
• Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006;17:1638–44
   PubMed Web of Science ®Google Scholar
• Tankó LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003;32:421–6
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. EJC Supplements 2004;2:9–12
   Web of Science ®Google Scholar
• Lee SM, Chang YS, Kim CW, et al. Skills in handling turbuhaler, diskus, and pressurized metered-dose inhaler in Korean asthmatic patients. Allergy Asthma Immunol Res 2011;3:46–52
   PubMed Web of Science ®Google Scholar
• Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22:1725–35
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303–10
   PubMed Web of Science ®Google Scholar
• Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005;44:762–7
   PubMed Web of Science ®Google Scholar